Basaglar 100 Iu/ml 3 ml Cartridge

Basaglar 100 unit/ 3ml catridge is a prescription based medicine under doctor prescription. The medication is used in the treatment to maintain Type 1 and Type 2 diabetes mellitus. It belongs to the class of long-lasting insulin analogs which help regulate glucose levels throughout the day and night. patinersThe active ingredient of medicine is Insulin Glargine (3.64IU/ml) works by providing a steady, a long lasting release of insulin into the blood stream. It helps to control blood sugar levels in patients with disease.The exact dose and duration is correctly administered by the healthcare professional.

Provide insulin and maintain blood sugar level

Many medicines show side effects which are harmful for the body in various. Patients experience acute and severe symptoms while taking Basaglar 100 unit/ 3ml catridge. Consult with the healthcare provider before taking medications. Here are some side effects:
● Allergic reaction
● Rash
● Edema (swelling)
● Injection site reactions (pain, swelling and redness)
● Itching weight pain
● Weight gain
● Hypoglycemia (Low blood glucose level)
● Lipodystrophy ( skin thickening at the injection site)

Basaglar 100 can be used alone or in combination of other dietetic patients. Take the medicine at the fixed time everyday to everyday as per the dose to get the most benefit. Doctor recommendation is much needed while on the treatment. Do not stop or skip the medication as the blood sugar level may rise enormous, which may put the patient at high risk and this may increase the side effects. Consult the doctor before taking the medication.

Basaglar 100 unit/ 3ml catridge provide insulin to the body that helps to control the high blood (glucose) level. Insulin works by moving sugar into muscles and fat cells for energy and by reducing sugar production in the liver, helping to maintain healthy blood glucose level.

• Agent, A. D., & Tower, E. (2017). BASAGLAR™.
• Alert, I. P. S. Insulin Glargine.
• Abitbol, A., & Chu, L. (2025). What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives. Diabetes, Obesity and Metabolism.
• Monsonego, S. (2023). The use of biosimilar insulins in 2023. Canadian Diabetes & Endocrinology Today, 21-25.
• Lamb, Y. N., & Syed, Y. Y. (2018). LY2963016 insulin glargine: a review in type 1 and 2 diabetes. BioDrugs, 32(1), 91-98.